Summary

The global companion animal pharmaceuticals market is projected to reach USD 19.6 billion by 2027
from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.

“The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market.”
The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.

“In the forecast period, the dogs segment holds the largest share in the animal type segment.”
The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.

“In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market”
During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.

“By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period”
By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation: C-level–35%, Director Level–25%, and Others–40%
• By Region: North America–40%, Asia- Pacific–30%, Europe–20%, Middle East & Africa–5%, Latin America- 5%

The prominent players in the global companion animal pharmaceuticals market are Zoetis, Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (US), Eco Animal Health Group PlC (UK), Virbac (France), Dechra Pharmaceuticals PLC (UK), Vetoquinol (France), Neogen Corporation (US), Orion Group (Finland), Zenex Animal Health India Private Limited (India), Norbrook Holdings Limited (UK), Chanelle Pharma (Ireland), HIPRA (Spain), Ceva Sante Animale (France), Tianjin Ringpu Bio-Technology Co Ltd. (China), Kyoritsu Seiyaku (Japan), Endovac Animal Health (US), Indian Immunologicals Ltd (India), Ashish Life Sciences Pvt Ltd (India), Lutim Pharma Pvt Ltd (India), Biogénesis Bagó (US), Brilliant Bio Pharma (India), Intas Pharmaceuticals (India), and Vetindia Pharmaceuticals limited (India).

Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
• Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.2.2 MARKETS COVERED 33
FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION 33
1.2.3 YEARS CONSIDERED 33
1.3 CURRENCY CONSIDERED 34
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 34
1.4 LIMITATIONS 34
1.5 STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35
1.6.1 REFINEMENTS IN SEGMENTS OF GLOBAL MARKET 35
1.6.2 UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS 35
1.6.3 UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS 35
1.6.4 ADDITION OF RECESSION IMPACT 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY RESEARCH 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY RESEARCH 38
2.1.2.1 Primary sources 39
2.1.2.2 Key data from primary sources 40
2.1.2.3 Key industry insights 41
2.1.2.4 Breakdown of primaries 42
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.2 MARKET SIZE ESTIMATION 42
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 43
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC. 43
FIGURE 6 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS 44
FIGURE 7 MARKET ANALYSIS APPROACH 45
FIGURE 8 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH 45
FIGURE 9 TOP-DOWN APPROACH 46
FIGURE 10 CAGR PROJECTIONS 47
FIGURE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET (2022–2027): IMPACT ANALYSIS ON DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
2.3 DATA TRIANGULATION APPROACH 50
FIGURE 12 DATA TRIANGULATION METHODOLOGY 50
2.4 MARKET SHARE ESTIMATION 51
2.5 STUDY ASSUMPTIONS 51
2.6 RISK ASSESSMENT 52
2.7 LIMITATIONS 52
2.7.1 METHODOLOGY-RELATED LIMITATIONS 52
2.7.2 SCOPE-RELATED LIMITATIONS 52
2.8 IMPACT OF RECESSION 52
3 EXECUTIVE SUMMARY 53
FIGURE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION) 53
FIGURE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION) 54
FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION) 54
FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION) 55
FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHICAL SNAPSHOT 56
4 PREMIUM INSIGHTS 57
4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW 57
FIGURE 18 INCREASING PREVALENCE OF ZOONOTIC DISEASES AND RISING PET OWNERSHIP RATES WORLDWIDE TO DRIVE MARKET 57
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021) 58
FIGURE 19 INFECTIOUS DISEASES SEGMENT IN GERMANY ACCOUNTED FOR LARGEST SHARE IN 2021 58
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 20 CHINA & INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 59
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022–2027) 60
FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 60
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS 60
FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 60
 
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 62
FIGURE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
5.2.1 MARKET DRIVERS 62
5.2.1.1 Rising prevalence of zoonotic diseases 62
TABLE 2 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2019) 63
5.2.1.2 Rising demand for pet insurance due to growing animal health expenditure 64
TABLE 3 US: AVERAGE PREMIUM RATES (2019–2021) 64
FIGURE 24 CANADA: AVERAGE ANNUAL PREMIUMS (2017–2021) 64
TABLE 4 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION) 65
5.2.1.3 Increasing R&D investments for animal healthcare 65
5.2.1.4 Rising awareness initiatives by government agencies and animal welfare organizations 66
5.2.1.5 High pet ownership rates worldwide 67
TABLE 5 PET POPULATION, BY ANIMAL, 2014–2020 (MILLION) 67
TABLE 6 MARKET DRIVERS: IMPACT ANALYSIS 68
5.2.2 MARKET RESTRAINTS 68
5.2.2.1 Rising pet care costs 68
FIGURE 25 US: PET INDUSTRY EXPENDITURE, 2010–2020 69
5.2.2.2 Limited number of novel pharmaceuticals for veterinary care 69
5.2.2.3 High cost of vaccines and complexities associated with storage 69
5.2.2.4 Growing resistance to antimicrobials and antibiotics 70
TABLE 7 MARKET RESTRAINTS: IMPACT ANALYSIS 71
5.2.3 MARKET OPPORTUNITIES 71
5.2.3.1 Lucrative growth opportunities in emerging markets 71
5.2.3.2 Growing prevalence of chronic animal diseases 72
5.2.3.3 Rising technological advancements in vaccine manufacturing 72
TABLE 8 MARKET OPPORTUNITIES: IMPACT ANALYSIS 73
5.2.4 MARKET CHALLENGES 73
5.2.4.1 Stringent regulatory approval process for pharmaceuticals 73
5.2.4.2 Limited awareness of vaccine coverage 73
5.2.4.3 Misdiagnosis due to diversity of parasites 74
5.2.4.4 Low animal healthcare expenditure in emerging markets 74
TABLE 9 MARKET CHALLENGES: IMPACT ANALYSIS 74
 
6 INDUSTRY INSIGHTS 75
6.1 INTRODUCTION 75
6.2 INDUSTRY TRENDS 75
6.2.1 RISING ACQUISITIONS OF SMALLER COMPANIES BY GLOBAL PLAYERS 75
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET: MAJOR ACQUISITIONS (2017–2022) 76
6.2.2 INCREASING PRODUCT INNOVATIONS FOR ANIMAL HEALTHCARE 76
TABLE 11 INNOVATIVE COMPANION ANIMAL PHARMACEUTICAL TRENDS 77
6.2.3 EXPANDING VETERINARY BUSINESSES WORLDWIDE 77
6.3 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 12 PORTER’S FIVE FORCES ANALYSIS 78
6.3.1 THREAT OF NEW ENTRANTS 78
6.3.2 THREAT OF SUBSTITUTES 79
6.3.3 BARGAINING POWER OF SUPPLIERS 79
6.3.4 BARGAINING POWER OF BUYERS 79
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 79
6.4 REGULATORY ANALYSIS 80
FIGURE 26 COMPANION ANIMAL PHARMACEUTICAL MARKET: DEVELOPMENT AND APPROVAL PROCESS FOR PRODUCTS 81
TABLE 13 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS 82
FIGURE 27 COMPANION ANIMAL PHARMACEUTICAL MARKET: PRODUCT APPROVAL PROCESS IN EUROPE 83
6.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
6.4.1.1 US 84
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
6.4.1.2 Europe 86
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
6.4.1.3 Rest of the World 87
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
6.5 VALUE CHAIN ANALYSIS 87
FIGURE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS 88
6.6 SUPPLY CHAIN ANALYSIS 88
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS 90
6.7 ECOSYSTEM ANALYSIS 90
6.7.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 90
FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 91
6.8 PATENT ANALYSIS 91
6.8.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: PATENT ANALYSIS TRENDS 91
FIGURE 31 PATENT PUBLICATION TRENDS (JANUARY 2013–DECEMBER 2022) 91
6.8.2 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS 92
FIGURE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET: TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR PATENTS (2017–2022) 92
6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS 93
FIGURE 33 COMPANION ANIMAL PHARMACEUTICAL MARKET: TOP APPLICANT COUNTRIES FOR PATENTS (2017–2022) 93
6.9 PRICING ANALYSIS 93
TABLE 17 AVERAGE SELLING PRICES OF COMPANION ANIMAL PHARMACEUTICALS BY APPLICATION (USD) 93
6.10 KEY CONFERENCES AND EVENTS FROM 2023 TO 2024 94
TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET: CONFERENCES AND EVENTS 94
6.11 KEY STAKEHOLDERS & BUYING CRITERIA 95
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
FIGURE 34 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS 95
TABLE 19 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS 95
FIGURE 35 BUYING CRITERIA 96
TABLE 20 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 96
6.12 TRADE ANALYSIS 96
7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION 97
7.1 INTRODUCTION 98
TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 98
7.2 INFECTIOUS DISEASES 98
TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 99
TABLE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 99
7.2.1 PARASITICIDES 100
7.2.1.1 Growing regulatory guidelines to control parasite-related diseases to fuel market 100
TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
7.2.2 VACCINES 101
7.2.2.1 Growing awareness among pet owners for canine & feline vaccines to drive market 101
TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 103
7.2.3 ANTIBIOTICS AND ANTIMICROBIALS 103
7.2.3.1 Effective prevention for clinical and subclinical diseases in companion animals to fuel uptake 103
TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2020–2027 (USD MILLION) 104
7.2.4 OTHERS 105
TABLE 27 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2027 (USD MILLION) 106
7.3 DERMATOLOGIC DISEASES 106
7.3.1 RISING CASES OF DERMATITIS DUE TO NUTRITIONAL DEFICIENCIES TO DRIVE MARKET 106
TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 107
7.4 PAIN 108
7.4.1 RISING DEMAND FOR ANTI-INFLAMMATORY DRUGS AND OPIOIDS TO DRIVE MARKET 108
TABLE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2020–2027 (USD MILLION) 109
7.5 ORTHOPEDIC DISEASES 109
7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS DUE TO INCREASING OBESITY IN PETS TO DRIVE MARKET 109
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 110
7.6 BEHAVIORAL DISORDERS 110
7.6.1 INCREASING AWARENESS AMONG PET OWNERS FOR APPROPRIATE PET BEHAVIOR TO SUPPORT MARKET GROWTH 110
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 111
7.7 OTHER INDICATIONS 112
TABLE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 113
8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION 114
8.1 INTRODUCTION 115
TABLE 33 ROUTES OF ADMINISTRATION FOR KEY COMPANION ANIMAL PHARMACEUTICALS 115
TABLE 34 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 116
8.2 ORAL ADMINISTRATION 116
8.2.1 ABILITY TO TREAT A WIDE RANGE OF DISEASES AND AFFORDABILITY OF MEDICATION TO DRIVE DEMAND 116
TABLE 35 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 117
8.3 INJECTABLE ADMINISTRATION 117
8.3.1 ADVANTAGES OF COMPLETE ABSORPTION AND BIOAVAILABILITY TO FUEL MARKET 117
TABLE 36 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INJECTABLE ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 118
 
8.4 TOPICAL ADMINISTRATION 118
8.4.1 TEMPORARY EFFECTS OF TOPICAL DRUGS COMPARED TO ORAL AND PARENTERAL DRUGS TO RESTRAIN MARKET 118
TABLE 37 COMPANION ANIMAL PHARMACEUTICAL MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 119
9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE 120
9.1 INTRODUCTION 121
TABLE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 121
9.2 DOGS 121
9.2.1 RISING PET DOG POPULATION WORLDWIDE TO DRIVE MARKET 121
FIGURE 36 GROWING PET DOG POPULATION IN INDIA (MILLION) 122
FIGURE 37 POPULATION OF PET DOGS GLOBALLY (MILLION) 123
TABLE 39 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2020–2027 (USD MILLION) 123
9.3 CATS 124
9.3.1 INCREASING R&D ACTIVITIES ON FELINE HEALTH TO DRIVE MARKET 124
TABLE 40 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2020–2027 (USD MILLION) 125
9.4 HORSES 125
9.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 125
TABLE 41 HORSE POPULATION, BY REGION, 2016–2020 (MILLION) 126
TABLE 42 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2020–2027 (USD MILLION) 127
9.5 OTHER COMPANION ANIMALS 127
TABLE 43 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION) 128
10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 129
10.1 INTRODUCTION 130
TABLE 44 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 130
10.2 VETERINARY HOSPITALS 130
10.2.1 GROWING FOCUS ON HEALTHCARE AND COMPANION ANIMAL DIAGNOSTIC SERVICES TO DRIVE MARKET 130
TABLE 45 VETERINARY VISIT EXPENSES FOR CATS AND DOGS (US) 131
TABLE 46 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 131
10.3 VETERINARY CLINICS 132
10.3.1 RISING NUMBER OF PRIVATE CLINICAL PRACTICES TO DRIVE MARKET 132
TABLE 47 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY (2019 VS. 2021) 132
TABLE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 133
10.4 RETAIL PHARMACIES 134
10.4.1 ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTIONS AND OTC MEDICATION TO SUPPORT MARKET GROWTH 134
TABLE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION) 135
11 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION 136
11.1 INTRODUCTION 137
TABLE 50 COMPANION ANIMAL POPULATION, BY COUNTRY, 2022 (THOUSAND) 137
FIGURE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT 138
TABLE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2020–2027 (USD MILLION) 138
11.2 NORTH AMERICA 139
FIGURE 39 EXPECTED GROWTH FOR NUMBER OF VETERINARIANS IN NORTH AMERICA (2012 VS. 2030) 140
11.2.1 NORTH AMERICA: RECESSION IMPACT 140
FIGURE 40 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT 141
TABLE 52 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 53 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 142
TABLE 54 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 55 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 142
TABLE 56 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 143
TABLE 57 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 143
11.2.2 US 143
11.2.2.1 Rising pet expenditure to fuel market 143
FIGURE 41 US: POPULATION OF DOGS, 2012–2020 (MILLION) 144
FIGURE 42 US: EXPENDITURE ON VET VISITS, 2013–2020 144
TABLE 58 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2019–2021 144
TABLE 59 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 145
TABLE 60 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 61 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 145
TABLE 62 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 146
TABLE 63 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 146
11.2.3 CANADA 146
11.2.3.1 Increasing pet ownership rates to drive demand for vaccines 146
TABLE 64 CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION) 147
TABLE 65 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 147
TABLE 66 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 67 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 148
TABLE 68 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 148
TABLE 69 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 148
11.3 EUROPE 149
TABLE 70 EUROPE: COMPANION ANIMAL POPULATION, 2021 (MILLION) 149
TABLE 71 EUROPE: NUMBER OF VETERINARIANS, 2014–2020 150
11.3.1 EUROPE: RECESSION IMPACT 150
TABLE 72 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 73 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 151
TABLE 74 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 75 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 151
TABLE 76 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 152
TABLE 77 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 152
11.3.2 GERMANY 152
11.3.2.1 Rising focus on animal health due to increasing vet practices to drive market 152
TABLE 78 GERMANY: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION) 153
TABLE 79 GERMANY: NUMBER OF VETERINARIANS, 2015 VS. 2020 153
TABLE 80 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 153
TABLE 81 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 82 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 154
TABLE 83 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 154
TABLE 84 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 155
 
11.3.3 UK 155
11.3.3.1 Availability of animal health insurance policies to fuel market for pharmaceuticals 155
TABLE 85 UK: COMPANION ANIMAL POPULATION, 2017–2020 (MILLION) 155
TABLE 86 UK: NUMBER OF VETERINARIANS, 2016 VS. 2020 156
TABLE 87 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 156
TABLE 88 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 89 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 157
TABLE 90 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 157
TABLE 91 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 157
11.3.4 FRANCE 158
11.3.4.1 Rising prevalence of infectious diseases to drive demand for animal health products 158
TABLE 92 FRANCE: COMPANION ANIMAL POPULATION, 2010–2021 (MILLION) 158
TABLE 93 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 159
TABLE 94 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 95 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 159
TABLE 96 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 160
TABLE 97 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 160
11.3.5 SPAIN 160
11.3.5.1 Increasing adoption rates of dogs and cats to fuel market 160
TABLE 98 SPAIN: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION) 161
TABLE 99 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 161
TABLE 100 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 101 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 162
TABLE 102 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 162
TABLE 103 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 162
11.3.6 ITALY 163
11.3.6.1 Lucrative animal and pet health sectors to drive market growth 163
TABLE 104 ITALY: PET POPULATION, 2017–2021 (MILLION) 163
TABLE 105 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 163
TABLE 106 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 107 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 164
TABLE 108 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 164
TABLE 109 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 165
11.3.7 REST OF EUROPE 165
TABLE 110 REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION) 165
TABLE 111 REST OF EUROPE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2019 VS. 2020 166
TABLE 112 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 166
TABLE 113 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 114 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 167
TABLE 115 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 167
TABLE 116 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 168
11.4 ASIA PACIFIC 168
11.4.1 ASIA PACIFIC: RECESSION IMPACT 168
FIGURE 43 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT 169
TABLE 117 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 118 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 170
TABLE 119 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 120 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 171
TABLE 121 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 171
TABLE 122 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 171
11.4.2 CHINA 172
11.4.2.1 Rising number of zoonotic & infectious diseases in animals to drive market 172
FIGURE 44 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 173
TABLE 123 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 173
TABLE 124 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 125 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 174
TABLE 126 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 174
TABLE 127 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 175
11.4.3 JAPAN 175
11.4.3.1 Rising demand for imported breeds to support market growth 175
TABLE 128 JAPAN: DOMESTICATED DOG AND CAT POPULATION, 2012–2020 (THOUSAND) 175
TABLE 129 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 176
TABLE 130 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 131 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 176
TABLE 132 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 177
TABLE 133 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 177
11.4.4 INDIA 177
11.4.4.1 Rising focus on pet care due to a large population of domesticated animals to drive market 177
FIGURE 45 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 178
TABLE 134 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 178
TABLE 135 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 136 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 179
TABLE 137 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 179
TABLE 138 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 180
11.4.5 SOUTH KOREA 180
11.4.5.1 Pet care initiatives for street dogs and cats to fuel market for animal care products 180
TABLE 139 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 181
TABLE 140 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 141 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 181
TABLE 142 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 182
TABLE 143 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 182
 
11.4.6 AUSTRALIA 182
11.4.6.1 Growing awareness of parasitic infections to drive demand for parasiticides 182
FIGURE 46 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 183
TABLE 144 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 183
TABLE 145 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 146 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 184
TABLE 147 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 184
TABLE 148 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 185
11.4.7 REST OF ASIA PACIFIC 185
TABLE 149 REST OF ASIA PACIFIC: NUMBER OF VETERINARIANS, 2012−2021 185
TABLE 150 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 186
TABLE 151 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 152 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 186
TABLE 153 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 187
TABLE 154 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 187
11.5 LATIN AMERICA 187
11.5.1 GROWING POOL OF SKILLED VETERINARIANS OWING TO RISING PET POPULATION TO DRIVE MARKET 187
TABLE 155 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICA (2016 VS. 2019) 188
11.5.2 LATIN AMERICA: RECESSION IMPACT 188
TABLE 156 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 189
TABLE 157 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 158 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 189
TABLE 159 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 190
TABLE 160 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 190
11.6 MIDDLE EAST & AFRICA 190
11.6.1 EMERGING MARKET FOR ANIMAL HEALTHCARE PRACTISES TO SUPPORT UPTAKE 190
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 191
TABLE 161 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 191
TABLE 162 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 163 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 192
TABLE 164 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 192
TABLE 165 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 193
12 COMPETITIVE LANDSCAPE 194
12.1 OVERVIEW 194
FIGURE 47 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS (2019–2022) 195
12.2 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS 195
FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET: REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2017–2021) 196
12.3 MARKET SHARE ANALYSIS 196
FIGURE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2021) 197
12.4 COMPANY EVALUATION QUADRANT 198
12.4.1 STARS 198
12.4.2 EMERGING LEADERS 199
12.4.3 PERVASIVE PLAYERS 199
12.4.4 PARTICIPANTS 199
FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPANY EVALUATION QUADRANT (2021) 200
12.5 EVALUATION QUADRANT FOR STARTUPS/SMES 200
12.5.1 PROGRESSIVE COMPANIES 200
12.5.2 DYNAMIC COMPANIES 201
12.5.3 STARTING BLOCKS 201
12.5.4 RESPONSIVE COMPANIES 201
FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: STARTUPS/SME EVALUATION QUADRANT (2021) 201
12.6 COMPETITIVE BENCHMARKING 202
TABLE 166 COMPANION ANIMAL PHARMACEUTICALS MARKET: INDICATION PORTFOLIO ANALYSIS: 202
TABLE 167 COMPANION ANIMAL PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION PORTFOLIO ANALYSIS 203
TABLE 168 COMPANION ANIMAL PHARMACEUTICALS MARKET: ANIMAL TYPE PORTFOLIO ANALYSIS 205
TABLE 169 COMPANION ANIMAL PHARMACEUTICALS MARKET: DISTRIBUTION CHANNEL PORTFOLIO ANALYSIS 206
12.7 COMPANY GEOGRAPHIC FOOTPRINT 207
TABLE 170 COMPANION ANIMAL PHARMACEUTICALS MARKET: REGIONAL REVENUE MIX 207
 
12.8 COMPETITIVE SITUATION AND TRENDS 208
12.8.1 PRODUCT LAUNCHES & APPROVALS 208
TABLE 171 PRODUCT LAUNCHES & APPROVALS 208
12.8.2 DEALS 210
TABLE 172 DEALS 210
12.8.3 OTHER DEVELOPMENTS 213
TABLE 173 OTHER DEVELOPMENTS 213
13 COMPANY PROFILES 214
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 KEY PLAYERS 214
13.1.1 ZOETIS INC. 214
TABLE 174 ZOETIS INC.: BUSINESS OVERVIEW 214
FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2021) 215
13.1.2 MERCK & CO., INC. 219
TABLE 175 MERCK & CO., INC.: BUSINESS OVERVIEW 219
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2021) 220
13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 224
TABLE 176 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW 224
FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2021) 225
13.1.4 ELANCO ANIMAL HEALTH INCORPORATED 229
TABLE 177 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW 229
FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2021) 230
13.1.5 VIRBAC 234
TABLE 178 VIRBAC: BUSINESS OVERVIEW 234
FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2021) 235
13.1.6 DECHRA PHARMACEUTICALS PLC 238
TABLE 179 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW 238
FIGURE 57 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2021) 239
13.1.7 VETOQUINOL 243
TABLE 180 VETOQUINOL: BUSINESS OVERVIEW 243
FIGURE 58 VETOQUINOL: COMPANY SNAPSHOT (2021) 244
13.1.8 NEOGEN CORPORATION 247
TABLE 181 NEOGEN CORPORATION: BUSINESS OVERVIEW 247
FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT (2021) 247
13.1.9 ORION GROUP 249
TABLE 182 ORION GROUP: BUSINESS OVERVIEW 249
FIGURE 60 ORION GROUP: COMPANY SNAPSHOT (2021) 250
13.1.10 ECO ANIMAL HEALTH GROUP PLC 252
TABLE 183 ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW 252
FIGURE 61 ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSHOT (2021) 253
 
13.2 OTHER PLAYERS 254
13.2.1 ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED 254
13.2.2 NORBROOK 255
13.2.3 CHANELLE PHARMA 256
13.2.4 HIPRA 257
13.2.5 CEVA SANTÉ ANIMALE 257
13.2.6 TIANJIN RINPU BIO-TECHNOLOGY CO., LTD. 259
13.2.7 KYORITSU SEIYAKU 260
13.2.8 ENDOVAC ANIMAL HEALTH 261
13.2.9 INDIAN IMMUNOLOGICALS LTD. 261
13.2.10 ASHISH LIFE SCIENCE PVT. LTD. 262
13.2.11 PHARMA PVT. LTD. 263
13.2.12 BIOGENESIS BAGO S.A. 264
13.2.13 INTAS PHARMACEUTICALS 265
13.2.14 BRILLIANT BIOPHARMA 266
13.2.15 VETINDIA PHARMACEUTICALS LIMITED 267
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 268
14.1 INDUSTRY EXPERT INSIGHTS 268
14.2 DISCUSSION GUIDE 269
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 273
14.4 CUSTOMIZATION OPTIONS 275
14.5 RELATED REPORTS 275
14.6 AUTHOR DETAILS 276